AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 04/24/20

In a statement , the FDA is cautioning against the use of malaria meds chloroquine and hydroxychloroquine outside of the hospital setting for the treatment of COVID-19 due to the risk of adverse heart rhythm side effects. More news on: Tekla World Healthcare Fund, BlackRock Health Science...

The FDA has approved Amneal Pharmaceuticals' (NYSE: AMRX ) Abbreviated New Drug Application for a generic version of Butrans (buprenorphine) Transdermal System, 5 mcg/hr, 7.5 mcg/hr, 10 mcg/hr, 15 mcg/hr and 20 mcg/hr. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks ne...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Butrans ® (buprenorphine) T...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) will be a virtual meeting instead of an in-person meeting. This change is in response to the ongo...

Amneal Pharmaceuticals (NYSE: AMRX ) may soon run out of the raw ingredients to make hydroxychloroquine because Finland is keeping the drug for domestic use, the company's co-CEOs tell Reuters. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

States across the U.S. are instituting measures to prevent hoarding of malaria drugs hydroxychloroquine and chloroquine in an effort to maintain supply amid acute demand from pharmacies and COVID-19 patients. More news on: Tekla World Healthcare Fund, BlackRock Health Sciences Trust, The...

Chloroquine and hydroxychloroquine aren't approved by the Food and Drug Administration to treat COVID-19, the disease caused by the novel coronavirus, but the agency has granted an emergency-use authorization for the drugs, which were originally developed to treat malaria. In Europe however...

The FDA is requesting all manufacturers of ranitidine drugs to withdraw them immediately from the U.S. market due to the presence of an impurity called N-Nitrosodimethylamine (NDMA), a suspected carcinogen. More news on: GlaxoSmithKline plc, Amneal Pharmaceuticals, Inc., Mylan N.V., Heal...

In a note, UBS regards the republished results from one of the first randomized trials evaluating malaria drug hydroxychloroquine (HCQ) in COVID-19 patients as "inconclusive." More news on: Tekla World Healthcare Fund, BlackRock Health Sciences Trust, The Gabelli Healthcare & Well...

Plus Therapeutics. (NASDAQ: PSTV ) +63%   in-licenses novel oncology candidates. More news on: Plus Therapeutics, Inc., Bellerophon Therapeutics, Inc., Owens & Minor, Inc., Stocks on the move, , Read more ...